Oppenheimer Maintains Outperform on Definium Therapeutics, Raises Price Target to $60

Benzinga Newsdesk www.benzinga.com Positive 90.8%

Neg 0% Neu 0% Pos 90.8%

Oppenheimer analyst Jay Olson maintains Definium Therapeutics (NASDAQ:DFTX) with a Outperform and raises the price target from $40 to $60.